Related Experiment Video

Updated: Feb 24, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.3K

What's new in paediatric hypertension?

Rowena Lalji1,2, Kjell Tullus1

  • 1Departmentof Paediatric Nephrology, Great Ormond Street Hospital for Children, London, UK.

Archives of Disease in Childhood
|August 19, 2017
PubMed

Insights

Childhood hypertension increases adult cardiovascular risks, yet screening is lacking. Early diagnosis requires multiple readings, and salt restriction may benefit children, especially those consuming processed foods.

Area of Science:

  • Pediatric Nephrology
  • Cardiovascular Health
  • Public Health

Background:

  • Childhood hypertension is a precursor to adult hypertension and cardiovascular disease.
  • Current screening practices for pediatric hypertension are insufficient despite established guidelines.
  • Accurate diagnosis is complicated by frequent false-positive blood pressure readings, necessitating multiple measurements.

Purpose of the Study:

  • To highlight the challenges in diagnosing pediatric hypertension.
  • To emphasize the need for specific blood pressure targets in at-risk pediatric subgroups.
  • To advocate for population-based salt restriction in children due to rising processed food intake.

Main Methods:

  • Review of current guidelines and diagnostic challenges in pediatric hypertension.
  • Analysis of potential underestimation of hypertension in overweight/obese children.
  • Examination of the role of dietary salt intake as a cardiovascular risk factor.

Main Results:

  • Hypertension in overweight and obese children may be underestimated by up to 20% based on normative data sets.
  • Specific blood pressure targets are crucial for subgroups like adolescents, children with chronic kidney disease (CKD), and type 1 diabetes.
  • High salt intake is a significant risk factor for cardiovascular disease in children.

Conclusions:

  • Addressing pediatric hypertension is critical for long-term cardiovascular health.
  • Improved screening and diagnostic protocols are needed for early detection.
  • Population-level salt reduction strategies could mitigate cardiovascular risks in children.

Keywords:
General PaediatricsNephrologyPaediatric PracticeScreeningVascular Disease

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.7K
Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats04:20

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

639

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
329
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
644
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
359
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
506
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
286